My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Bristol-Myers Squibb (NY:BMY)

60.64 -0.13 (-0.21%)

Streaming Delayed Price Updated: 11:40 AM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Bristol-Myers Squibb

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms

April 28, 2022

From Bristol Myers Squibb

Via Business Wire

Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027

April 13, 2022

Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...

Via FinancialNewsMedia

Bristol-Myers Squibb Company (BMY) Climbs to Annual-High Share Price

April 08, 2022

Via Investor Brand Network

Bristol-Myers Squibb Company (BMY) Climbs to Annual-High Share Price

April 08, 2022

Via Investor Brand Network

Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

April 11, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter

April 11, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma

April 05, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...

April 05, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...

April 05, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%

April 05, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten

April 03, 2022

From Bristol Myers Squibb

Via Business Wire

Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial

April 02, 2022

From Bristol Myers Squibb

Via Business Wire

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

March 29, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application

March 25, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session

March 21, 2022

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma

March 18, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

March 14, 2022

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

February 28, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1...

February 25, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma...

February 25, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%

February 25, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.

February 18, 2022

SOURCE: Bristol Myers Squibb Company

Via 3BL Media

Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis

February 17, 2022

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma

February 17, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy

February 16, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes

February 15, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion

February 15, 2022

From Bristol Myers Squibb

Via Business Wire

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

February 14, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements

February 09, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.

February 08, 2022

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.